Novo Nordisk laid out a growth strategy at its Capital Markets Day built around new obesity and diabetes drugs to follow Wegovy and Ozempic, whose key patents expire in the early 2030s. Investors pushed the stock lower anyway, unimpressed by targets that merely match industry averages. The company is also leaning on early adoption of its oral Wegovy pill, launched ahead of Eli Lilly's Foundayo, to defend share in the fast-growing weight-loss pill market.
Source: https://www.cnbc.com/2026/09/25/novo-eli-lilly-obesity-drugs.html